ClinicalTrials.gg
RecruitingNCT07054515Updated Oct 27, 2026

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

A Phase 3 interventional study of AZ-3102 and Placebo in Niemann-Pick Type C Disease, GM1 Gangliosidosis and GM2 Gangliosidosis, sponsored by Azafaros B.V.. Recruiting at 39 sites in 17 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Azafaros B.V. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 27, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Niemann-Pick Disease, Type C with a site in United States — 6 open to participants now, 8 under way, 4 of them phase 3. Niemann-Pick Disease, Type C · United States.

Planned enrollment
Largest of 17
147 · median 33
Started
2025
with 1 other
Phase 3
5 of 23
3 open now
Registered
22nd of 23
by date
Lead sponsor
2 of 23
Azafaros B.V.

Among the 23 studies in Niemann-Pick Disease, Type C with a site in United States, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 22nd registered.

Niemann-Pick Disease, Type C

37 studies on the registry are indexed under Niemann-Pick Disease, Type C; 8 are open to participants now.

Browse Niemann-Pick Disease, Type C studies →

Open to participants now

6 of the 23 studies in Niemann-Pick Disease, Type C with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Niemann-Pick Disease, Type C studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Niemann-Pick Disease, Type C with a site in United States, or all of them as a file.
02

Study summary

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis

Read the detailed description

This is a Phase 3 randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in multiple disease areas using a Master Protocol Research Program. Participants are randomized to different subprotocols based on disease type: Niemann-Pick type C (NPC), GM1 gangliosidosis or GM2 gangliosidosis.

Treatment specific procedures will be described in the disease-specific subprotocol. Individual subprotocols may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding subprotocols.

For information specific to each individual subprotocol included in this trial, please refer to the corresponding, separate, clinicaltrials.gov records: Niemann-Pick type C disease NCT07082725 (Recruiting) and GM1 gangliosidosis or GM2 gangliosidosis NCT07082543 (Active, not recruiting - No longer looking for participants) .

03

Conditions studied

  • Niemann-Pick Type C Disease
  • GM1 Gangliosidosis
  • GM2 Gangliosidosis

Keywords

  • Nizubaglustat
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants, aged 4 years and older with a diagnosis of the late-infantile or juvenile form of NPC disease. Detailed inclusion criteria are presented in the NPC disease-specific subprotocol AZA-001-301-NPC (NCT07082725).
  • Male and female participants, aged 4 years and older with a diagnosis of GM1 or GM2 (Tay-Sachs, Sandhoff, or GM2AB variant disease) gangliosidosis of late-infantile/ juvenile onset. Detailed inclusion criteria are presented in the GM1/GM2 gangliosidosis-specific subprotocol AZA-001-301-GMx (NCT07082543).

Exclusion criteria

Exclusion Criteria:

  • Detailed exclusion criteria are presented in the NPC disease-specific subprotocol AZA-001-301-NPC
  • Detailed exclusion criteria are presented in the GM1/GM2 gangliosidosis-specific subprotocol AZA-001-301-GMx
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (estimated)

Study arms

  • Experimental
    Subprotocol NCT07082725: Intervention Group NPC

    Participants will be randomized to receive either nizubaglustat or placebo at a 2:1 ratio (nizubaglustat:placebo). (Recruiting)

    Drug: AZ-3102 · Drug: Placebo

  • Experimental
    Subprotocol NCT07082543: Intervention Group GM1/GM2

    Participants will be randomized to receive either nizubaglustat or placebo at a 2:1 ratio (nizubaglustat:placebo). (Active, not recruiting - No longer looking for participants)

    Drug: AZ-3102 · Drug: Placebo

Interventions

  • Oral dispersible tablets

    Also known as: nizubaglustat

  • DrugPlacebo

    A matching placebo will be administered in the same regimen as the intervention

06

What researchers measure

Primary outcomes

  1. Number of participants allocated to subprotocol AZA-001-301-NPC

    Time frame: Baseline to month 18

  2. Number of participants allocated to subprotocol AZA-001-301-GMx

    Time frame: Baseline to month 18

07

Study locations

29 of 39 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Jun 30, 2025
Primary completionEst.
May 14, 2028
CompletionEst.
Jun 14, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Royal Manchester Children's Hospital is now Recruiting
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Royal Manchester Children's Hospital is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07054515
Lead sponsor
Azafaros B.V.
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jun 30, 2025
Primary completion
May 14, 2028 (estimated)
Completion
Jun 14, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Patient Advocacy Representative
Contact
info@azafaros.com
Please reach out by email
Contact for Healthcare Professionals
Contact
medinfo@azafaros.com
Please reach out by email

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nizubaglustat

Start the discussion